• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

供体肝移植后乙型肝炎病毒相关肝细胞癌早期复发的术前风险分层:五八模型的建立和验证。

Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine; Institution of Organ Transplantation, Zhejiang University, Hangzhou, 310003, China.

NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, Zhejiang Province, China.

出版信息

BMC Cancer. 2019 Nov 21;19(1):1136. doi: 10.1186/s12885-019-6343-4.

DOI:10.1186/s12885-019-6343-4
PMID:31752756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6873730/
Abstract

BACKGROUND

Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is associated with poor surgical outcomes. This study aims to construct a preoperative model to predict individual risk of post-LT HCC recurrence.

METHODS

Data of 748 adult patients who underwent deceased donor LT for HCC between January 2015, and February 2019 were collected retrospectively from the China Liver Transplant Registry database and randomly divided into training (n = 486) and validation(n = 262) cohorts. A multivariate analysis was performed and the five-eight model was developed.

RESULTS

A total of 748 patients were included in the study; of them, 96% had hepatitis B virus (HBV) and 84% had cirrhosis. Pre-LT serum alpha-fetoprotein (AFP), tumor number and largest tumor diameter were incorporated to construct the 5-8 model which can stratify patients accurately according to their risk of recurrence into three prognostic subgroups; low-(0-5 points), medium-(6-8 points) and high-risk (> 8 points) with 2-year post-LT recurrence rate of (5,20 and 51%,p <  0.001) respectively. The 5-8 model was better than Milan, Hangzhou, and AFP-model for prediction of HCC early recurrence. These findings were confirmed by the results of the validation cohort.

CONCLUSIONS

The 5-8 model is a simple validated and accurate tool for preoperative stratification of early recurrence of HCC after LT.

摘要

背景

肝移植(LT)后肝细胞癌(HCC)的早期复发与手术结果不佳有关。本研究旨在构建一个术前模型,以预测 LT 后 HCC 复发的个体风险。

方法

回顾性收集了 2015 年 1 月至 2019 年 2 月期间,来自中国肝移植注册数据库的 748 例成人接受尸肝 LT 治疗 HCC 的患者数据,并将其随机分为训练(n=486)和验证(n=262)队列。进行多变量分析并建立五八模型。

结果

共有 748 例患者纳入研究,其中 96%患有乙型肝炎病毒(HBV),84%患有肝硬化。将术前血清甲胎蛋白(AFP)、肿瘤数量和最大肿瘤直径纳入构建五八模型,该模型可根据患者的复发风险将其准确分层为三个预后亚组;低危(0-5 分)、中危(6-8 分)和高危(>8 分),2 年 LT 后复发率分别为(5%、20%和 51%,p<0.001)。五八模型优于米兰、杭州和 AFP 模型,用于预测 HCC 早期复发。验证队列的结果证实了这些发现。

结论

五八模型是一种简单、验证良好且准确的 LT 后 HCC 早期复发的术前分层工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/69dc942b13c5/12885_2019_6343_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/5a93158ab7d7/12885_2019_6343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/39fc67166563/12885_2019_6343_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/fdfdb68510c7/12885_2019_6343_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/69dc942b13c5/12885_2019_6343_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/5a93158ab7d7/12885_2019_6343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/39fc67166563/12885_2019_6343_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/fdfdb68510c7/12885_2019_6343_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b8/6873730/69dc942b13c5/12885_2019_6343_Fig4_HTML.jpg

相似文献

1
Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.供体肝移植后乙型肝炎病毒相关肝细胞癌早期复发的术前风险分层:五八模型的建立和验证。
BMC Cancer. 2019 Nov 21;19(1):1136. doi: 10.1186/s12885-019-6343-4.
2
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.验证 AFP 模型作为预测病毒肝炎相关性肝硬化患者 HCC 复发的指标,这些患者因 HCC 已接受肝移植。
J Hepatol. 2017 Mar;66(3):552-559. doi: 10.1016/j.jhep.2016.10.038. Epub 2016 Nov 27.
3
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
4
Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.肝硬化患者接受尸体供肝肝移植后肝细胞癌早期复发的预测:一项多中心研究
Ann Transplant. 2019 Aug 20;24:489-498. doi: 10.12659/AOT.917296.
5
Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.肝移植后肝细胞癌复发的危险因素:单中心经验中甲胎蛋白模型的准确性
Transplant Proc. 2015 Jan-Feb;47(1):84-9. doi: 10.1016/j.transproceed.2014.12.013.
6
Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria.活体肝移植后乙型肝炎与肝细胞癌复发:米兰标准的作用
Turk J Gastroenterol. 2019 Jan;30(1):75-80. doi: 10.5152/tjg.2018.18794.
7
Histological differentiation predicts post-liver transplantation survival time.组织学分化可预测肝移植后的生存时间。
Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):201-8. doi: 10.1016/j.clinre.2013.11.002. Epub 2013 Dec 30.
8
The Matching Status Between Donor and Recipient Hepatitis B Seroepidemiology Makes a Difference in Liver Transplantation for Hepatocellular Carcinoma.供体与受体乙肝血清流行病学的匹配状态对肝细胞癌肝移植有影响。
Clin Transl Gastroenterol. 2020 May;11(5):e00168. doi: 10.14309/ctg.0000000000000168.
9
Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.糖尿病可能影响乙型肝炎病毒相关肝细胞癌患者肝移植后的长期生存。
World J Gastroenterol. 2016 Nov 21;22(43):9571-9585. doi: 10.3748/wjg.v22.i43.9571.
10
Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria.比较米兰标准、复旦上海标准和杭州标准用于乙肝相关肝细胞癌肝移植患者的生存率和肿瘤复发率。
J Dig Dis. 2013 Oct;14(10):552-8. doi: 10.1111/1751-2980.12083.

引用本文的文献

1
A Hybrid Machine Learning Model Based on Semantic Information Can Optimize Treatment Decision for Naïve Single 3-5-cm HCC Patients.基于语义信息的混合机器学习模型可优化初治单发3-5厘米肝癌患者的治疗决策。
Liver Cancer. 2022 Jan 28;11(3):256-267. doi: 10.1159/000522123. eCollection 2022 Jun.
2
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.肝癌患者肝移植选择标准的预后作用:网络荟萃分析。
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab130.
3
Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma.

本文引用的文献

1
The changing epidemiology of liver diseases in the Asia-Pacific region.亚太地区肝脏疾病的不断变化的流行病学。
Nat Rev Gastroenterol Hepatol. 2019 Jan;16(1):57-73. doi: 10.1038/s41575-018-0055-0.
2
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南:肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
3
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
预测乙型肝炎病毒相关肝细胞癌术后并发症模型的开发
Front Oncol. 2021 Oct 5;11:717826. doi: 10.3389/fonc.2021.717826. eCollection 2021.
4
Biomarkers for hepatocellular carcinoma based on body fluids and feces.基于体液和粪便的肝细胞癌生物标志物。
World J Gastrointest Oncol. 2021 May 15;13(5):351-365. doi: 10.4251/wjgo.v13.i5.351.
5
Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation.肝移植术后乙型肝炎病毒相关肝细胞癌患者基于炎症的预后评分
J Hepatocell Carcinoma. 2020 Jul 7;7:101-106. doi: 10.2147/JHC.S259992. eCollection 2020.
肝细胞癌的诊断、分期及管理:美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
4
Hepatocellular carcinoma.肝细胞癌。
Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.
5
Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need.肝移植后肝细胞癌复发风险的预测模型:仍是一项未被满足的需求。
Liver Int. 2017 May;37(5):648-650. doi: 10.1111/liv.13417.
6
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.肝移植治疗肝细胞癌:结果与新型手术方法。
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5.
7
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.验证一种用于肝移植后肝细胞癌复发的肿瘤复发风险评估(RETREAT)评分。
JAMA Oncol. 2017 Apr 1;3(4):493-500. doi: 10.1001/jamaoncol.2016.5116.
8
Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.不产生甲胎蛋白的肝细胞癌患者的评估。
JAMA Surg. 2017 Jan 1;152(1):55-64. doi: 10.1001/jamasurg.2016.3310.
9
Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.肝细胞癌肝移植后的复发:故事的新寓意。
Ann Surg. 2017 Mar;265(3):557-564. doi: 10.1097/SLA.0000000000001966.
10
Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria.血清肿瘤标志物在为超出米兰标准的肝细胞癌患者选择肝移植候选者时提供了更精确的预后评估。
Ann Surg. 2016 May;263(5):842-50. doi: 10.1097/SLA.0000000000001578.